LETTER TO THE EDITOR

An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes

Patric Teodorescu,[1,2] Sergiu Pasca,[1] Inyoung Choi,[1] Cynthia Shams,[1] W. Brian Dalton,[1] Lukasz P. Gondek,[1] Amy E. DeZern[1] and Gabriel Ghiaur[1]

[1]Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA and [2]Universitatea de Medicina si Farmacie "Iuliu Hatieganu", Cluj-Napoca, Romania

Correspondence:
G. GHIAUR - gghiaur1@jhmi.edu

https://doi.org/10.3324/haematol.2023.282967

Received: March 6, 2023.
Accepted: June 29, 2023.
Early view: July 6, 2023.

Supplementary Figure 1

A. Spleen



25.5% ± 2.65 (n=4) | 40.07% ± 8.1 (n=4) | 0.16% ± 0.05 (n=3) | 0.25% ± 0.1 (n=4)

B. Bone Marrow



0.95% ± 0.26 (n=4) | 0.67% ± 0.05 (n=4) | 0.16% ± 0.05 (n=3) | 0.03% ± 0.05 (n=4)

C.

Primary sample	Strain		Mouse ID	%hCD45+		
				PB	BM	Spleen
Patient 1	NSG		#20	0.2	0.5	N/A
			#21	0	0.1	0.03
			#22	0	2	0.02
	NSGS		#11	7.3	8.8	16.4
			#10	11.2	14.9	54.9
			#30	N/A	14.4	N/A
Patient 2	NSG		#300	0.2	1.4	0.2
			#302	0.6	1.1	0.2
	NSGS		#P10	9.4	26.1	11.2
			#P11	12.8	25.1	12.9
			#P30	7.5	18.1	14.5
Patient 3	NSGS	no Aza	#160	3.7	94.3	9.8
			#162	3.1	96.9	8.1
			#164	20.7	99.3	31.3
		Aza	#161	20.3	69.4	22.5
			#163	2.6	41.4	12.7

Supplemental Figure 1. Clodronate depletes macrophages in the spleen and BM of NSGS mice, allowing for engraftment of primary low-risk MDS

(A) Clodronate, but not XRT, depletes >99% of mouse spleen macrophages at 2 and 7 days. **(B)** Clodronate, but not XRT, depletes 83% of mouse BM macrophages at 2 days, and 97% at 7 days. **(C)** Table showing levels of engraftment in individual mice, in PB, BM and spleen, at the time of sacrificing. Percentages represent $hCD45^+$ cells out of ($mCD45^+$ + $hCD45^+$) cells.